UNIGE document Scientific Article
previous document  unige:94309  next document
add to browser collection
Title

Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework

Authors
Chiotis, Konstantinos
Saint-Aubert, Laure
Gietl, Anton
Picco, Agnese
Varrone, Andrea
Herholz, Karl
show hidden authors show all authors [1 - 10]
Published in Neurobiology of Aging. 2017, vol. 52, p. 214-227
Abstract The use of biomarkers has been proposed for diagnosing Alzheimer's disease in recent criteria, but some biomarkers have not been sufficiently investigated to justify their routine clinical use. Here, we evaluate in a literature review the clinical validity of amyloid positron emission tomography (PET) imaging using a structured framework developed for the assessment of oncological biomarkers. Homogenous criteria have been addressed in reviews of other Alzheimer's disease biomarkers. There is adequate evidence that the main aims of phases 1 (rationale for use) and 2 (discriminative ability) have been achieved. The aims of phase 3 (early detection ability) have been partly achieved, while phase 4 studies (performance in representative mild cognitive impairment patients) are currently ongoing. Phase 5 studies (quantification of impact and costs) are still to come. This review highlights the priorities to be pursued to enable the proper use of amyloid PET imaging in a clinical setting. Future investigations will primarily be large, phase 4 studies that will assess the utility of amyloid PET imaging in routine clinical practice.
Identifiers
PMID: 28317650
Full text
Article (Published version) (1 MB) - document accessible for UNIGE members only Limited access to UNIGE
Structures
Research group Laboratoire de neuroimagerie et de traceurs moléculaires innovants (984)
Citation
(ISO format)
CHIOTIS, Konstantinos et al. Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. In: Neurobiology of Aging, 2017, vol. 52, p. 214-227. https://archive-ouverte.unige.ch/unige:94309

16 hits

0 download

Update

Deposited on : 2017-05-16

Export document
Format :
Citation style :